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ABSTRACT
The use of the ammonia deprotection step to introduce
15N labels at specific exocyclic amino positions of
adenine, cytosine, guanine or 2-aminopurine of
oligodeoxynucleotides is described.
INTRODUCTION
One of the problems found during the structural elucidation of
synthetic oligonucleotides by NMR is the difficulty in detecting
the amino protons. The introduction of a 15N label in the
exocyclic amino group in combination with special pulse
techniques allows the selective observation of specific base pairs.
The methodology described for introduction of '5N into
oligonucleotides is based on the preparation of 15N labelled
nucleoside derivatives conveniently protected for DNA
synthesisl-8. Recently, the development of nucleoside
derivatives that can be transformed to different nucleoside
analogues during deprotection has been described9-12. This
method, named 'the convertible nucleoside approach', has been
used very recently to prepare an oligodeoxynucleotide containing
a cytidine 15N labelled at position 413. In the present communi-
cation we describe the preparation of oligodeoxynucleotides
containing a 15N label at the exocyclic position of any of the
three natural bases that have amino groups (A, C, and G) and
a non-natural, mutagenic base (2-aminopurine). The methodology
described here uses the ammonia deprotection step to incorporate
the 15N label. Previous reports have shown that this strategy is
succesful for the specific labeling of exocyclic amino groups of
cytidine residues in DNA'3-15.
RESULTS AND DISCUSSION
Selection of nucleoside precursors
The aim of this work is to use '5N aqueous ammonia solution
to deprotect and introduce a 15N label at a predetermined
exocyclic amino group in oligodeoxynucleotides. First of all it
was necessary to check whether commercially available 15N
aqueous ammonia, supplied as a 3.3 N solution, is sufficient to
deprotect standard solid phase protecting groups (Bzl for A and
C and ibu for G). The concentration of aqueous ammonia
normally used for oligonucleotide deprotection is 15 N but the
large excess of ammonia can be reduced if longer deprotection
times are used, especially if oligonucleotides are short (as it is
the case in oligonucleotides for NMR studies). The hexamer
5'GCTAGC 3' was prepared using standard solid phase
oligonucleotide synthesis protocols. Deprotection was run with
3.3 N aqueous ammonia (0.3 ml for 10 mg of oligonucleotide-
CPG) at 60°C for 2 days. HPLC analysis of the product gave
a major product that had the correct nucleoside composition (data
not shown). So, we conclude that 3.3 N aqueous solutions can
be used for deprotection of short oligonucleotides. It is obvious
that a more concentrated ammonia solution (prepared by
dissolving 15NH3 gas in water) could be used if desired.
The next step was to design and prepare suitable
phosphoramidite derivatives. The following criteria were taken
in account: a) the nucleoside derivative should be functionalized
for DNA synthesis b) it should be stable to DNA synthesis
conditions, and c) it should be transformed to the desired
nucleoside with 3.3 N ammonia solutions in a reasonable time
(not more than three days at 60°C) and without side-products
(at least 95% purity).
Following these criteria we selected the 4-(l,2,4-triazolyl)-
(dUtri) and 04-ethyl (dUet) derivatives of 2-deoxyuridine as
precursors of 4-(15N)-dC (figure 1). The phosphoramidites of
dUri and 04-aryl-dU have been used to prepare oligonucleotides
containing 15N labeled cytidine'3-15. In the present work, we
have compared the use of dUtri with 04-ethyl-dU (dUet)
derivatives for the 15N labelling of position 4 of C. The 04-ethyl
derivative has been selected because the reactivity is higher and
the preparation easier16 than the 04-aryl derivatives9"10'1317.
For the introduction of 15N amino groups at the position 2 of
guanine and 2-aminopurine, we have selected the corresponding
2-fluoropurine derivatives (figure 1). 2-Fluoro-dI derivatives have
been described to react with amines giving several guanine
derivatives at nucleoside'8-20 and oligonucleotide2' level. The
protection of the 06 position with the 2-(4-nitrophenyl)ethyl
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Figure 1. Nucleoside derivatives prepared in this work for the introduction of
'5N labels at exocyclic amino groups.
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Figure 2. Preparation of 2-fluoropurine 2'-deoxyriboside phosphoramidite.
(Npe) group is needed for the preparation of 2-fluoro-dI
derivative18-21 and, in principle it could be removed after the
fluorination reaction21 but it is preferable to leave it on during
the preparation of the phosphoramidite and during DNA
synthesis. 2-Fluoropurine-2'-deoxyriboside has not been
previously described.
Finally, for the labelling of the exocyclic amino groups of
adenine with 15N we selected 6-fluoropurine, 6-chloropurine and
06-aryl-dI derivatives. Similarly to guanine, 6-fluoro and
6-chloro derivatives have been described to react with amines
to produce adenine adducts at nucleoside19, 22-24 and
oligonucleotide21'25 level. On the other hand, 06-aryl-dI
derivatives have been described for the preparation of
oligonucleotides containing modified adenines"l-12.
Figure 3. Preparation of 2-fluoro-06-Npe-2'-deoxyinosine phosphoramidite.
Preparation of nucleoside precursors
DMT-dUli phosphoramidite was prepared by reacting DMT-dU
phosphoramidite with phosphoryl tris(1,2,4-triazolide) as
described by Webb and Matteucci26. The fluorescent derivative
was purified by silica gel as described for the TV" derivative27
obtaining the desired product in a 35% yield. The yield is lower
than the yield obtained for the T' derivative due to partial
decomposition during the silica gel purification. As observed by
MacMillan and Verdine9 the absence of the methyl group at
position 5 in the uracil derivative makes the triazolyl derivative
more reactive and consequently more difficult to isolate.
DMT-dUet was obtained by reacting DMT-dU with
phosphoryl tris(l,2,4-triazolide) followed by displacement of the
triazolyl group with sodium ethoxide'6 in a 60% overall yield.
Phosphorylation of the 3 '-OH was prevented by protection with
the trimethylsilyl group with trimethylsilyl-1,2,4-triazole as
described for DMT-04-ethyl-T16. The phosphoramidite
derivative was prepared following standard protocols.
2-Fluoropurine 2'-deoxyriboside was prepared by enzymatic
glycosylation (figure 2). First, 2-fluoropurine (2) was prepared
in a 64% yield by reacting 2-aminopurine (1) with sodium nitrite
and tetrafluoroboric acid28. Conversion of 2-fluoropurine (2) to
its 2'-deoxyriboside (3) was performed using 2'-deoxycytidine
as glycosil donor and extracts from Lactobacillus helveticus
containing trans-N-glycosylase29. After silica gel purification,
compound 3 was obtained in a moderate (46%) yield
contaminated with 2-fluoropurine. This mixture was used for the
preparation of the DMT derivative (4) that was reacted with
chloro-N,N-diisopropyl-0-2-cyanoethyl phosphine to obtain the
phosphoramidite 5.
2-Fluoropurine-06-Npe-2'-deoxyinosine (8) was prepared by
fluoride displacement of the diazonium derivative of 06-Npe-dG
(7) 18-21. Two different protocols have been tried. First,
compound 7 was reacted with sodium nitrite and tetrafluoroboric
acid in water-acetone mixtures. Second, the same compound was
reacted with t-butylnitrite and HF/pyridine in anhydrous
media30. In both methods yields were moderate and some
depurination was observed. The yield from the aqueous protocol
was slightly better. Compound 7 was prepared following the
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Figure 4. Preparation of 2'-deoxyadenine precursors.
method described by the group of Pfleiderer31. The
corresponding phosphoramidite (10) was prepared following
standard protocols.
6-Chloropurine 2'-deoxyriboside (14) was the key product for
the preparation of different adenine precursors (figure 4). This
product is usually prepared2l-25 from 2'-deoxyinosine following
the method described by Robins and Basom32. We attempted the
direct replacement of the 6-amino group of dA by chlorine
described by Nair and Richardson33 because the starting dA is
less expensive than dI. 3',5'-O-bis (tert-butyldimethylsilyl)-dA
(12) was reacted with 1-pentyl nitrite34 in CC14 giving only the
desired 6-chloro intermediate (13) that was isolated in good yields
(63%). The formation of the dI derivative described by Gao and
Jones2 was not observed. The different results observed could
be due to the presence of water during diazotization reaction
coming from tetraethylammonium chloride used by these authors
as catalyst. 6-Fluoropurine 2'-deoxyriboside (15) was prepared
after two consecutive nucleophilic displacements at position 6.
First chlorine was displaced by N-methylpyrrolidine and the
resulting tetraalkylammonium salt was reacted with KF without
isolation. The method described is a modification of the standard
trimethylamine-mediated synthesis of 6-fluoropurines32'35 and
the use of N-methylpyrrolidine is preferred because it is easier
to handle than trimethylamine. Compound 15 was the only
product formed as judged by TLC and HPLC but attempts of
isolation by silica gel column chromatography failed probably
due to depurination during purification. When the crude
preparation was reacted with DMT chloride in pyridine, the DMT
derivative was formed and it could be isolated but with low yields
(16% from compound 14). The corresponding phosphoramidite
was prepared following standard protocols. The same route was
used for the preparation of 06-phenyl (16) and 06-pentafluoro-
phenyl (17) 2'-deoxyinosine derivatives (figure 4). These
compounds were isolated by silica gel column chromatography
with good yields.
Reactivity of nucleoside precursors to diluted ammonia
Prior to oligonucleotide synthesis, nucleoside precursors were
treated with 3.3 N ammonia solution at 60°C in order to estimate
the time needed to complete the ammonia displacement reaction.
2'-Deoxyuridine derivatives (dUtri and dUet) were not tested
because displacement was known to occur by diluted aqueous
ammonia in less than 10 hours by previous work with related
T and U derivatives'4- 16. Analysis of the products formed was
done by analytical reverse phase HPLC. Table 1 shows the results
obtained. All the nucleoside precursors gave the desired
2'-deoxynucleoside in 1 day of reaction except for 2-fluoro-
06-Npe-dI (7) and 06-phenyl-dI (16). In compound 7, the
displacement of the fluoride atom was faster but the removal of
the Npe group was very slow. Similarly, 2-fluoro-dI without the
Npe group was transformed to dG more rapidly and together with
2-fluoropurine 2'-deoxyriboside the ammonolysis was complete
after 24 hours. 6-Modified nucleoside precursors were more
reactive than 2-modified compounds. 6-Fluoropurine
2'-deoxyriboside (15) was converted to dA in less than 2 hours.
6-Chloropurine 2'-deoxyriboside (14) and 06-pentafluorophenyl-
dI (17) had similar reactivity (an overnight treatment is needed
for completion). 06-phenyl-dI (16) was the last reactive adenine
precursor that we made and hence was not used further.
Oligonucleotide syntheses
Sequences shown in table 2 were prepared on an automatic DNA
synthesizer using standard 2-cyanoethyl phosphoramidites and
the modified 2-cyanoethyl phosphoramidites described above.
Heptamers 5'GCGUtrGCC 3' and 5'GCGUetGCC 3' were
used to compare the two cytidine precursors. Oligonucleotide
supports were treated with 99% 15N aqueous ammonia at 60°C
for 3 days. One ml of commercially available 3.3 N solution was
used for a 2-3 mmol synthesis. After HPLC purification, the
15N labelled heptamer was obtained in a 68% yield when
04-ethyl-dU was used and in a 48% yield with the triazolyl
derivative. Enzymatic digestion of the oligonucleotide showed
the presence of a small amount of dU as side product coming
from the hydrolysis reaction instead of the ammonolysis. The
sequence prepared with the triazolyl derivative showed a small
amount of dU that corresponds to a 92% purity at the 15N
cytidine site while the sequence prepared with the 04-ethyl
derivative gave a 97% of purity. Proton and 15N NMR spectra
of both oligonucleotides confirm the selective labelling at the
position 4 of the predetermined cytidine (figure 5). Nonamer 5'
GTAGCN-l5GATC 3' was also prepared using 04-ethyl-dU
phosphoramidite with the same good results.
The complementary 9mer was prepared using the 2-amino-
purine precursor, 2-fluoropurine phosphoramidite (5). 15N-
Ammonia deprotection yielded a major product that was shown
to contain the desired 2-aminopurine by HPLC analysis of the
enzymatic digestion. The retention time and the characteristic
UV spectrum of the nucleoside confirmed the presence of the
mutagenic analogue. Neither starting 2-fluoropurine
2'-deoxyriboside or side-products were observed. Proton and
15N NMR spectra confirmed the structure and N selective
labelling of the oligonucleotide (data not shown).
A 20 mer oligonucleotide was prepared using compound 10
as the guanine precursor. After the assembly of the sequence,
one half of the support was treated directly with N aqueous
ammonia and the other half was treated with DBU to remove
the Npe group prior the ammonia treatment. The sample that
was treated with ammonia directly showed after 3 days of
treatment at 60°C two peaks with a similar retention time. The
HPLC analysis of the enzymatic digestions showed that the first
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Table 1. Reactivity of nucleoside precursors with 3.3 N aqueous ammonia at 60°C.
Starting nucleoside Reaction product Time for completion
2-Fluoro-06-Npe-dI, 7 dGa 48 hr
2-Fluoro-dI dG 24 hr
2-Fluoropurine 2'-deoxyriboside, 3 2-aminopurine dR 24 hr
6-Chloropurine 2'-deoxyriboside, 14 dA 16 hr
6-Fluoropurine 2'-deoxyriboside, 15 dA 90 min
o6-pentafluorophenyl-dI, 17 dA 16 hr
o6-phenyl-dI, 16 dA 48 hr
aO6-Npe-dG was formed first and slowly it was converted to dG.
Table 2. Oligonucleotide sequences prepared in this work.
SEQUENCE (5'> 3') Nucleoside Precursor 15N-Labelled nucleoside
A) GCGUtr'GCC 4-(1,2,4-triazolyl)-dU 4-'5N-dC
B) GCGUeCGCC 4-0-ethyl-dU 4-15N-dC
C) GTAGUetGATC 4-0-ethyl-dU 4-15N-dC
D) GATCP2FCTAC 2-fluoropurine dR 2-'5N-APdR
E) CGGCCGGAGAGAIFACGGCCCG 2-fluoro-06-Npe-dI 2-15N-dG
F) GCGAP6FTTCGCGC 6-fluoropurine dR 6-15N-dA
G) GCGAP6ClTTCGCGC 6-chloropurine dR 6-15N-dA
H) GCGAI'PTTCGCGC o6-pentafluorophenyl dI 6-15N-dA
peak was the desired oligonucleotide and second eluting peak
was the 20 mer that contained 06-Npe-dG. On the contrary, the
support treated previously with DBU gave only the desired
oligonucleotide containing 2-15N-dG. So, it could be concluded
that elimination of the Npe group with DBU prior ammonia
treatement is needed to obtain a complete conversion and
deprotection of the guanine precursor.
A dodecamer was prepared using the phosphoramidites of
compounds 14, 15 and 17 as adenine precursors. Deprotection
and modification were carried out with 15N-ammonia aqueous
solution as described above. Surprisingly, the HPLC
chromatograms obtained with the product coming from the 6-halo
derivatives 14 and 15 contained very small amounts of the desired
dodecamer. Instead a shorter oligonucleotide was obtained as the
major component. This side-product had a nucleoside composition
that corresponds to a sequence truncated at the modified
nucleoside. On the other hand, the oligonucleotide prepared with
compound 17 presented a correct HPLC chromatogram with a
major component that had a correct nucleoside composition.
Because coupling efficiencies of the phosphoramidites were high,
we thought that a severe depurination during the synthesis
followed by b-elimination of the apurinic site during the long
ammonia treatment was the reason of the failure of the 6-halo
derivatives. In order to check that hypothesis, we have measured
the depurination rates of compound 14 and 17. The half lives
of compounds 14 and 17 in 2% trichloroacetic acid in
dichioromethane were 20 min and 100 min respectively. Also,
the same sequence was prepared using 6-chloropurine
phosphoramidite and, after the addition of the 6-chloropurine
nucleoside, detritylation was carried out manually with 2M zinc
bromide in dichloromethane/isopropanol (85:15). Using these
conditions, depurination was reduced and the amount of desired
dodecamer was much higher. But, the best yield was obtained
when the phosphoramidite of compound 17 was used. HPLC
analysis of the enzymatic digestion of the desired dodecamer,
show the correct nucleoside composition. Neither starting
compound (17) or side-products were observed. 15N and proton
NMR spectra confirmed the presence of 6-15N adenine at the
desired site (figure 6).
In conclusion, we have shown that the amino groups of the
three natural bases and 2-aminopurine could be labeled with '5N
using the ammonia deprotection step. For that purpose, different
nucleoside precursors have been prepared, introduced to synthetic
oligonucleotides and tested for their ability to be labeled with
15N aqueous ammonia. In agreement to previous reports14- 15,
the phosphoramidite of Ui gave desired oligonucleotides
containing 4-15N cytidine, although the 04-ethyluracil derivative
is preferred. 2-Fluoropurine derivatives gave excellent results
for the preparation of 15N-labelled oligonucleotides at position
2 of 2-aminopurine and guanine. In contrast with previous
communications21,25, 6-fluoro and 6-chloropurine derivatives
were not efficient for producing oligonucleotides with 6-15N-
adenine probably due to depurination during the removal of the
DMT group. On the other hand, 06-pentafluorophenyl-dI
derivative gave the desired oligonucleotide with good yields,
indicating that 06-aryl-dI derivatives are more stable to DNA
synthesis conditions (in agreement with Ferentz and Verdine'2).
The method described here is of general applicability, efficient,
less expensive and simpler than previous methods. NMR studies
with the polymers prepared will be published elsewhere.
EXPERIMENTAL SECTION
Abbreviations
AcOEt : ethyl acetate, Bzl : benzoyl, DBU : 1,8-diaza-
bicyclo[5.4.0]undec-7-ene, DCM : dichloromethane, DEAD:
diethyl azodicarboxylate, DIEA : ethyldiisopropylamine, DMF
: N,N-dimethylformamide, DMT: dimethoxytrityl, dIPh:
06-phenyl-2'-deoxyinosine, dIPf: 06-pentafluorophenyl-2'-de-
oxyinosine, dIF : 2-fluoro-2'-deoxyinosine and its protected
derivative 2-fluoro-06-(4-nitrophenyl)ethyl-2'-deoxyinosine,
Et3N : triethylamine, ibu: isobutyryl, MeOH : methanol, Npe
: 2-(4-nitrophenyl)ethyl, p2F : 2-fluoropurine, p6F: 6-fluoro-
purine, p6Cl : 6-chloropurine, pyr: pyridine, TBDMS: tert-
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Figure 5. (a) 1H- spectrum of d(GCG*CGCC)2 at 25°C in H20, where *C =
'5NH2-dC. (b) '5N-filtered 'H- spectrum of d(GCG*CGCC)2 at 250C in H20.
The two doublets correspond to the two '5NH2 protons on *C. The resonance
at 8.4 ppm is aasigned to the amino proton which is hydrogen bonded to the
base-paired guanosine. The resonance at 6.5 ppm is assigned to the amino proton
which is not hydrogen bonded. Both resonances are split by 91 Hz, due to coupling
to the 15N.
butyldimethylsilyl, TFA: trifluoroacetic acid, THF: tetrahydro-
furan, Ttri: 4-(1 ,2,4-triazol-1-yl)-5-methyl-2-pyrimidon-2'-
deoxyriboside, Uet: 4-0-ethyl-uracil, Ut": 4-(1,2,4-triazol-1-yl)-
2-pyrimidone.
I-Pentyl nitrite was prepared as previosuly described34.
Trans-N-deoxyribosylase was isolated from Lactobacillus
helveticus as described previously29. DMT-dUtri N,N-diiso-
propyl-2-cyanoethyl phosphoramidite was prepared esentially as
described in ref. 26 and 27 (31P-NMR (CDC13, 121 MHz):
146.3 and 146.8 ppm). DMT-dUet N,N-diisopropyl-2-
cyanoethyl phosphoramidite was prepared following the method
described for the 0-4-ethylthymidine derivative16. 06-Npe-dG
(7) was prepared following the method described by Schirmeister
et al. with minor modifications31. 99% '5N-Ammonia aqueous
solution (3.3 N) was purchased to SDS (Isotopchim, France).
2-Fluoropurine (2)
2-Aminopurine (1) (1.35 gr, 10 mmol) was dissolved in 30 ml
of 48% aqueous HBF4 (3 ml/mmol of purine). The solution was
cooled at -10°C and 1.2 g (17 mmol) of sodium nitrite dissolved
in water (5 ml) were added dropwise during 40 min. After the
addition the mixture was stirred for 15 min and the temperature
was raised to 0 'C. The reaction was neutralized to pH 6 with
50% aqueous NaOH and the slurry was evaporated to dryness.
The residue was loaded onto a silica gel column with a 10%
MeOH solution in DCM and a 10 to 50% MeOH gradient in
DCM was used to elute the product giving 0.89 g (64% yield)
of a white solid. Rf (DCM/MeOH 8:2) : 0.84. 'H-NMR
(DMSO-d6, 300 MHz) : 9.0 (s, 1H, H-6); 8.6 (d, IH, H-8, 2.1
Hz). 19F-NMR (DMSO-d6, TFA as standard, 282 MHz) : 23.1
(s, IF, F-2).
2-Fluoropurine 2'-deoxyriboside (3)
400 mg of 2-fluoropurine (2) (3.0 mmol) was dissolved in 300
ml of water with 3.5 gr of 2'-deoxycytidine (15.7 mmol) as
2'-deoxyribose donor, 12 ml of the enzyme preparation (ref. 28,
0.07 units/ml) and 150 ml of 0.15 M Tris maleate buffer pH
6. The reaction was mantained at 37°C for 7 hours. The reaction
mixture was heated with boiling water for 6-7 min to denature
(a)
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Figure 6. (a) 'H NMR spectrum of d(GCGA*ATTCGCGC)2 at 25°C in H20,
where *A = 15NH2-dA. This sequence forms a symmetric duplex with 10 base
pairs, and a two-base overhang on the 3' end of each strand. The broad resonance
at 10.5 ppm is assigned to the imino proton of the overhanging G, which is partally
protected from exchange with solvent. (b) 15N NMR spectrum of d(GCG-
A*ATTCGCGC)2 at 250C in H20. The resonance is split into a triplet due to
coupling to the two amino protons. There is only one '5N resonance, indicating
one site of labelling. The l N-filtered 'H spectrum was not obtained due to the
broad linewidth of the adenosine amino proton resonances.
the protein and the mixture was concentrated to dryness. The
residue was treated with 10% MeOH in DCM to extract the
nucleosides and the solution was loaded onto a silica gel column
eluted with 10% MeOH in DCM. The fractions containing the
first eluted product were concentrated to dryness giving 350 mg
(46% yield) of the desired product contaminated with a 20% of
2-fluoropurine. This product was used without further
purification. Rf (DCM/ MeOH 8:2): 0.84. UV (CH3CN/H20
1:1) max. 266 nm. 'H-NMR (DMSO-d6, 300 MHz): 9.0 (s,
1H, H-6); 8.6 (s, 1H, H-8); 6.3 (t, 1H, H-i'); 5.3 (m, 1H,
5'-OH); 4.9 (m, 1H, 3'-OH); 4.2 (m, 1H, H-3'); 3.8 (s, 1H,
H4'); 3.5 (m, 2H, H-5'); 2.7 (m, 1H, H-2'); 2.3 (m, 1H, H-2').
'9F-NMR (DMSO-d6, TFA as reference, 282 MHz): 24.1 (s,
IF, F-2).
5'-O-(4,4'-dimethoxytrityl) 2-fluoropurine 2'-deoxyriboside
(4)
300 mg of the product obtained from enzymatic glycosylation
(approx. 1 mmol) were dried by coevaporation of dry pyridine.
The residue was dissolved in 10 ml of pyridine and 338 mg of
dimethoxytrityl chloride (1 mmol) were added. After magnetic
stirring for 16 hours MeOH (0.5 ml) was added and the mixture
was concentrated to dryness. The residue was purified by column
chromatography (silica gel) eluted with a 0 to 2% MeOH gradient
in DCM giving 140 mg (25% yield) of a yellowish oil.
5'-0-(4,4'-dimethoxytrityl) 2-fluoropurine 2'-deoxyriboside
3'-O-(2-cyanoethyl)-N,N-diisopropyl phosphoramidite (5)
140 mg of 5'-O-dimethoxytrityl-2-fluoropurine-2'-deoxyriboside
(4) (0.25 mmol) were dried by coevaporation with dry
acetonitrile. The residue was dissolved in dry DCM, 0.16 ml
(0.97 mmol) ofDIEA were added and the mixture was kept under
argon atmosphere. The solution was cooled with an ice bath and
87 mg (0.37 mmol) of chloro-2-cyanoethoxy-N,N-
diisopropylamino phosphine were added with a syringe. After
magnetic stirring for 1 hour at room temperature, MeOH (0.5
ml) was added and the solution was concentrated to dryness. The
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residue was dissolved in 10% Et3N in DCM and the solution
was washed with 5% aqueous NaCO3H and saturated aqueous
NaCl. The organic layer was dried with anhydrous Na2SO4 and
concentrated to dryness. The residue was purified by column
chromatography (silica gel) eluted with DCM / AcOEt / Et3N
(45:45: 10), giving 170 mg (89% yield) of the desired product.
Rf (DCM / AcOEt / Et3N 45:45:10) : 0.8.
2'-Deoxy-2-fluoro-0'[2-(4-nitrophenyl)ethyl]inosine (8)
Method 1. 2'-Deoxy-06-Npe-guanosine30 (7) (200 mg, 0.5
mmol) was dissolved in the minimum amount of acetone and the
solution was added to 1 ml of48% aqueous tetrafluoroboric acid
cooled at -20°C with vigorous stirring. A solution of 0.7 g (10
mmol) of sodium nitrite in 2 ml of water was gradually added
to the mixture. After the solution was added, the mixture was
stirred an additional 15 min at -20°C. The mixture was
neutralized with 50% aqueous sodium hydroxide and concentrated
to dryness. The residue was purified on a silica gel column eluted
with a 3 - 20 % MeOH gradient in DCM. Fractions containing
the desired product were pooled and evaporated to dryness
obtaining 70 mg of the main product (35% yield). HPLC
(conditions A) : Retention time 37.6 min. IH-NMR (200 MHz,
CDC13) : 8.5 (s, 1H, H-8); 8.1 (d, 2H, Ar); 7.6 (d, 2H, Ar);
6.3 (t, 1H, H-i'); 5.3 (d, OH-C(3')); 4.9 (t, OH-C(5')); 4.8 (t,
2H, CH20); 4.3 (m, 1H, H-3'); 3.8 (m, 1H, H-4'); 3.5 (m,
2H, H-5'); 3.2 (t, 2H, CH2-Phenyl); 2.6 (m, 1H, H-2'); 2.3 (m,
1H, H-2'). 19F-NMR ( 282 MHz, CDCl3, TFA as reference)
: 25.2 ppm (s), a small signal (approx. 5%) corresponding to
the depurinated product was observed at 25.5 ppm.
Method 2. To a stirred solution of 2'-deoxy-
06-[2-(4-nitrophenyl)ethyl] guanosine (7) (200 mg, 0.5 mmol)
in pyridine at -30°C, 2 ml of 65% HF / pyridine and 0.083
ml (0.7 mmol) of t-butylnitrite were added. After 5 min of
magnetic stirring at -30°C, the solution was neutralized with 50%
aqueous sodium hydroxide and concentrated to dryness. The
residue was purified on a silica gel column eluted with a 3-20%
MeOH gradient in DCM. Yield 40 mg (20%). The product
presented the same HPLC and NMR characteristics than the
product obtained by method 1.
2'-Deoxy-2-fluoroinosine
2'-Deoxy-2-fluoro-06-Npe-guanosine (8) (10 mg, 2.3 mmol)
was treated with 1.5 ml of 0.5 M DBU in dioxane. After 5 hours
of magnetic stirring, the solution was neutralized with 50%
aqueous acetic acid and concentrated to dryness. The product
was purified by column chromatography (silica gel) using a 5
to 20% MeOH gradient in DCM. Yield : 3 mg (48%). 19F-
NMR (282 MHz, CDCl3, TFA as reference) : 25.4 ppm (s).
5'-O-(dimethoxytrityl)-2'-deoxy-2-fluoro-06-[2-(4-nitro-
phenyl)ethyl] inosine (9)
To a solution of 2'-Deoxy-2-fluoro-06-Npe-guanosine (8, 300
mg, 0.7 mmol, coevaporated twice with dry pyridine) in 10 ml
of dry pyridine, dimethoxytrityl chloride (291 mg, 0.86 mmol)
was added and kept at room temperature for 5 hr. MeOH was
added (1 ml) and the mixture was evaporated. The residue was
dissolved in DCM and 5% aqueous sodium bicarbonate. The
organic phase was separated, washed with saturated aqueous
sodium chloride, dried with anhydrous sodium sulphate and
evaporated to dryness. The residue was purified by column
cromatography (silica gel) eluted with a 0-5% MeOH gradient
in DCM. Yield: 300 mg (58%).
5'-O-(dimethoxytrityl)-2'-deoxy-2-fluoro 06-[2-(4-nitro-
phenyl)ethyl] inosine-3'-O-(2-cyanoethyl-N,N-diisopropyl-
phosphoramidite) (10)
Compound 9 (150 mg, 0.15 mmol) was reacted with
chloro-2-cyanoethoxy-N,N- diisopropylamino phosphine (55 mg,
0.23 mmol) and DIEA (0.10 ml, 0.6 mmol) in anh. DCM under
argon atmosphere as described for compound 5. Yield: 170 mg
(95%). 31P-NMR (CDCl3, H3PO4 as internal reference)
149.42 and 149.38.
3',5'-Di-tert-butyldimethylsilyl-2'-deoxyadenosine (12)
2'-deoxyadenosine (11) (1 g, 5.8 mmol) and imidazole (3.2 g,
48 mmol) were dried by coevaporation with anhydrous toluene.
To the residue 20 ml of anhydrous DMF and 3.6 g of tert-
butyldimethylsilyl chloride (24 mmol) were added and the mixture
was stirred overnight at room temperature. Solvent was removed
using a vacuum pump and the residue was dissolved in DCM.
The organic solution was washed with water, dried with anh.
sodium sulphate and evaporated to dryness. The residue was
purified by silica gel column chromatography eluted with a
0-5% MeOH gradient in DCM giving 2.8 g (100%) of product
as a white powder. Rf (CH2C12 / MeOH 9:1): 0.82. 'H-NMR
(CDCl3) : 8.22 and 8.01 (s, 2H, H-2 and H-8); 6.33 (t, 1H,
H-i'); 5.82 (s, 2H, NH2); 4.50 (m, 1H, H-3'); 3.88 (m, 1H,
H-4'); 3.78 (m, 1H, H-5'); 3.69 (m, 1H, H-5'); 2.81 (m, 1H,
H-2'); 2.36 (m, 1H, H-2'); 0.93 and 0.87 (s, 18H, tBuSi); 0.14
and 0.06 (s, 12H, CH3Si).
3' ,5 ' -Di-tert-butyldimethylsilyl-6-chloropurine
2'-deoxyriboside (13)
3',5'-Di-tert-butyldimethylsilyl 2'-deoxyadenine (12) (2.8 g, 5.8
mmol) was dried by coevaporation with dry toluene. The residue
was dissolved with 100 ml of CC14 and 1.75 ml (13.1 mmol)
of 1-pentyl nitrite34 were added. The mixture was heated at
80°C under argon atmosphere and irradiated with a 200 watt
lamp. After one hour the mixture was evaporated and the residue
was purified by silica gel chromatography eluted with a 1-2%
gradient of MeOH in DCM giving the desired product as an oil
(1.8 g, 63% yield). Rf (CH2C12 / MeOH 95:5): 0.86. 'H-NMR
(CDCl3) : 8.63 and 8.32 (s, 2H, H-2 and H-8); 6.42 (t, 1H,
H-i'); 4.50 (m, 1H, H-3'); 3.88 (m, 1H, H4'); 3.78 (m, 1H,
H-5'); 3.69 (m, 1H, H-5'); 2.81 (m, 1H, H-2'); 2.36 (m, 1H,
H-2'); 0.93 and 0.87 (s, 18 H, tBuSi); 0.14 and 0.06 (s, 12H,
CH3Si).
6-Chloropurine 2'-deoxyriboside (14)
To a solution of 3',5'-di-tert-butyldimethylsilyl-6-chloropurine
2'-deoxyriboside (1.82 g, 3.6 mmol) in dry THF, a IM solution
of tetrabutylammonium fluoride (7.2 mmol) in THF was added.
After 15 min, the reaction was completed and the solvent was
removed by evaporation. The residue was dissolved in water,
the solution was washed with ethyl ether and the aqueous layer
was evaporated. The resulting oil was purified by silica gel
chromatography eluted with a 5-10% MeOH gradient in DCM
to give the desired product as an oil (0.98 g, 100% yield). Rf
(DCM / MeOH 95:5) : 0.15. UV(MeOH): X max. 264 nm.
HPLC (conditions A) : Retention time 16.4 min. IH-NMR
(CD30D) : 8.83 and 8.73 (s, 2H, H-2 and H-8); 6.57 (t, 1H,
H-i'); 4.60 (m, 1H, H4'); 3.82 (m, 1H, H-5'); 3.77 (m, 1H,
H-5'); 2.85 (m, 1H, H-2'); 2.55 (m, 1H, H-2').
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6-Fluoropurine 2'-deoxyriboside (15)
To a solution of 6-chloropurine 2'-deoxyriboside (14) (0.45 g,
1.7 mmol) in anhydrous DCM cooled with ice, 1.6 ml (14.9
mmol) of 1-methylpyrrolidine was added and the reaction mixture
was stirred for 2 hours at 0°C. At that time, the reaction was
complete as shown by the formation of the pyrrolidinium salt
by TLC (Rf = 0, DCM / MeOH 9:1). The reaction mixture
was warmed at room temperature and evaporated to dryness. The
resulting oil was used without further purification.
To a stirred suspension of potassium fluoride (spray dried,
Fluka, 0.96 g, 1.7 mmol) in dry DMF mantained at 40°C, a
solution of the pyrrolidinium salt (prepared as described above,
1.7 mmol) in DMF was added. After magnetic stirring for 4 hours
at 40°C, the reaction mixture was cooled and filtered and the
solution was concentrated to dryness. The resulting oil was used
without further purification. Attempts at silica gel column
purification at this stage resulted on low recoveries of the product.
Rf (DCM / MeOH 9:1): 0.2. HPLC (conditions A) : retention
time 15.1 min. 1H-NMR (CDC13): 8.74 and 8.63 (s, 2H, H-2
and H-8); 6.53 (t, 1H, H-i'); 4.86 (m, 1H, H-3'); 4.15 (m, 1H,
H-4'); 3.94 (m, 1H, H-5'); 3.79 (m, IH, H-5'); 2.81 (m, 1H,
H-2'); 2.36 (m, 1H, H-2'). 19F-NMR (DMSO-d6, TFA as
reference) : 3.73 (s, iF, 6-F). U.V. (H20) : 247.6 nm (7.000).
5'-O-(4,4'-dimethoxytrityl)-6fluoropurine 2'-deoxyriboside
(18)
6-Fluoropurine 2'-deoxyriboside (15, 0.4 g, 1.6 mmol) was
reacted with dimethoxytrityl chloride (0.82 g, 2.4 mmol) in
pyridine as described for compound 9. Yield: 0.12 g (16% yield
from 6-chloropurine 2'-deoxyriboside). Rf (DCM/MeOH 9:1)
: 0.6. 1H-NMR (CDCl3): 8.55 and 8.24 (s, 2H, H-2 and H-8);
7.3 (m, 9H, DMT); 6.80 (m, 4H, DMT); 6.51 (t, 1H, H-1');
4.71 (m, 1H, H-3'); 4.17 (m, 1H, H-4'); 3.78 (s, 6H, -OCH3);
3.42 (m, 2H, H-5'); 2.87 (m, 1H, H-2'); 2.63 (m, 1H, H-2').
5'-O-(4,4'-dimethoxytrityl)-6fluoropurine 2'-deoxyriboside
3'-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (19)
5'-O-Dimethoxytrityl-6-fluoropurine 2'-deoxyriboside (0.12 g,
0.21 mmol) was reacted with chloro-2-cyanoethoxy-N,N-
diisopropylamino phosphine (76 mg, 0.32 mmol) and DLEA (0.15
ml, 0.86 mmol) in dry DCM as described for compound 5. Yield:
0.1 g (64%). Rf(CHCl3 / AcOEt / NEt3): 0.88.
6-O-phenyl-2'-deoxyinosine (16)
A solution of 0.3 g (1.1 mmol) of 6-chloropurine 2'-deoxy-
riboside (14) in dry DCM (20 ml) was cooled with ice and 1.1
ml (10 mmol) of 1-methylpyrrolidine were added. After magnetic
stirring for 2 hrs at 0°C, phenol (11 mmol) and Et3N (0.5 ml,
3.3 mmol) were added and the mixture was heated under reflux
for 2 hr and evaporated to dryness. The residue was purified
on silica gel column chromatography eluted with a 5% MeOH
solution in DCM to give compound 16 as an oil. Yield : 0.24
g (66%). 'H and 13C-NMR identical to the product described
by Ferentz and Verdine'2.
6-0-pentafluorophenyl-2'-deoxyinosine (17)
A solution of 0.5 g (1.8 mmol) of 6-chloropurine 2'-deoxy-
riboside (14) in dry DCM (30 ml) was cooled with ice and 1.8
ml (16.6 mmol) of 1-methylpyrrolidine were added. After
magnetic stirring for 2 hr at 0°C, pentafluorophenol (3.4 g, 18.5
mmol) and Et3N (0.77 ml, 5.5 mmol) were added and the
residue was purified on silica gel column chromatography eluted
with a 5% MeOH solution in DCM to give compound 17 as
brown-red oil. Yield: 80%. Rf (DCM / MeOH 9:1) : 0.52.
UV(MeOH): X max. 254 am. 1H-NMR (CDCl3) : 8.54 and
8.32 (each s, 2H, H-2 and H-8), 6.53 (q, IH, H-i'), 4.82 (d,
1H, H-3'), 4.35 (s, IH, H4'), 4.05 (q, 2H, H-5'), 2.98 (m,
1H, H-2'), 2.58 (m, IH, H-2'). 19F-NMR (CDCl3, TFA
internal reference) : -95.82 (m), -89.63 (m), -87.95 (m),
-81.82 (s), -76.63 (t).
5'-O-(4,4'-dimethoxytrityl)-6-pentafluorophenyl-2'-deoxy-
inosine (20)
Compound 17 (0.3 g, 0.7 mmol) was reacted with dimethoxytrityl
chloride (0.27 g, 1.1 mmol) in dry pyridine as described for
compound 9. Yield : 0.21 g (42%). Rf (DCM / MeOH 9:1):
0.8. 'H-NMR (CDC13): 8.45 and 8.32 (each s, 2H, H-2 and
H-8), 7.32 (m, SH, Ph DMT), 7.30 and 6.80 (m, 8H, Ph-OMe
DMT), 6.51 (t, 1H, H-i'), 4.75 (m, 1H, H-3'), 4.26 (q, IH,
H-4'), 3.78 (s, 6H, -OMe DMT), 3.42 (m, 2H, H-5'), 2.85 (m,
1H, H-2'), 2.59 (m, 1H, H-2'). 19F-NMR (CDC13, TFA
internal reference): -96.52 (s), -89.95 (q), -86.82 (i),
-82.65 (t), -76.5 (q).
5'-O-(4,4'-dimethoxytrityl)-6-pentafluorophenyl-2'-deoxy-
inosine 3'-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite
(21)
Compound 20 (0.2 g, 0.3 mmol) was reacted with 2-cyanoethyl-
N,N-diisopropyl chlorophosphoramidite (72 mg, 0.3 mmol) and
dry Et3N (0.087 ml, 0.63 mmol) as described for compound 5.
Yield: 0.13 g (50%). Rf (AcOEt / CHC13 / Et3N 45: 45: 10)
= 0.76. 19F-NMR (CDCl3, TFA as internal reference): -88.4
(s), -86.7 (m), -82.6 (m), -79.5 (s), -76.4 (m). 31P-NMR
(H3PO4 as internal reference): 149.5 (s).
Conversion of modified 2'-deoxynucleosides to their amino
derivatives
Approx. 1 mg of each nucleoside derivative (see table 1) was
treated with 0.5 ml of 3.3 N aqueous ammonia solution at 60°C.
At different time intervals, an aliquot of the solution was taken
and analyzed by HPLC (conditions A). In all cases, the
conversion to the desired nucleoside gave only the desired
product. The reaction of ammonia with 2'-deoxy-2-fluoro-
O&Npe-inosine (8) gave an intermediate product that coeluted
with O&Npe-dG and this product slowly was converted to the
desired dG.
Depurination studies
Approx. 1 mg of compounds 14 and 17 were disolved in 2%
trichloroacetic acid in DCM (0.5 ml). At different times 0.1 ml
aliquots were taken, neutralized with 0.1 ml of a 2% triethylamine
in DCM and the solvents evaporated. The residue was
resuspended with MeOH / water (1:1) and analyzed by HPLC.
Retention times: compound 14: 16.4 min, depurinated product:
13.05 (conditions A). Retention times: compound 17: 18.2 min,
depurinated product: 19.2 min (conditions C). Half time for
depurination of compound 14: 20 min, half time for depurination
of compound 17: 100 min.
Oligonucleotide synthesis
The sequences shown in table 2 were prepared on a Applied
Biosystems automatic DNA synthesizer using standardmixture was refluxed for 2 hr and evaporated to dryness. The
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2-cyanoethyl phosphoramidites and the modified phosphor-
amidites described above.
Oligonucleotide-supports were treated with 99% 15N aqueous
ammonia (3.3 N solution) at 60°C for 2-3 days. 1 ml of
ammonia solution was used for 2-3 mmol synthesis. The
oligonucleotide sample containing 2-fluoro-06-Npe-dI was
divided in two parts. One half was treated directly with N
ammonia. The other half was treated first with a 0.5 M DBU
solution in acetonitrile for one hour at room temperature (2
washes of 30 min), washed with acetonitrile, 1 % solution of
triethylamine in acetonitrile (to remove DBU) and acetonitrile,
and after, the support was treated with 15N ammonia. As
described in results, the DBU deprotection before the ammonia
treatment is important to obtain a complete removal of the Npe
group. The ammonia solutions were concentrated to dryness and
the products were purified by reverse phase HPLC. All syntheses
presented a major peak that was collected and analyzed by snake
venom phosphodiesterase and alkaline phosphatase digestion
followed by HPLC analysis of the nucleosides (conditions B) 16.
Yield (O.D. units at 260 nm): Heptamer A (2 mmol synthesis):
35 O.D.; heptamer B (2 mmol): 53 O.D.; nonamer C (3 mmol):
300 O.D.; nonamer D (2 mmol): 135 O.D.; 20 mer E (1.5
mmol, with removal of Npe before ammonia) 100 O.D.;
Dodecamer H (2 mmol) 70 O.D.
HPLC conditions
In all cases solvent A was 20 mM triethylammonium acetate (pH
7.8) and solvent B was a 1: 1 mixture of water and acetonitrile.
For analytical runs the following conditions were used. Column:
Nucleosil 120C18, 250x4 mm, flow rate: 1 ml/min. A) 5-95%
B linear gradient in 40 minutes. B) 5-50% B linear gradient
in 20 minutes.C) 40-100% B linear gradient in 20 minutes. For
semipreparative runs the following conditions were used:
Columns : Nucleosil 120C18, 250x10 mm and C4Vydac,
250x 10 mm. Flow rate: 3 ml / min. A 5-50%B linear gradient
in 30 minutes.
NMR measurements
HPLC purified oligonucleotides were further purified by flow
dialysis using a 1000 MWCO membrane against 200-300 mM
NaCl, 20-30 mM NaCl, and finally against 2H20 for 1 day
each. The fmal sample buffer contained 10 mM potassium
phosphate in a 90:10 (vol/vol) H20/2H20 solution. The pH was
7.0 and the sample volume was 0.5 ml. DNA concentrations for
samples were 0.4-2.0 mM in duplex.
NMR spectra were acquired on a Bruker AMX-600
spectrometer. All spectra were recorded at 25 OC. All 'H
spectra were collected into 8192 data points using a spectral widht
of 12000-13000 Hz. 256 scans were acquired, with a recycle
time of 2s. The solvent resonance was suppressed using a 1-1
pulse sequence. 15N-filtered 'H spectra were obtained using a
pulse sequence described previously36. '5N spectra were
collected into 8192 data points using a spectral width of
12000-19000 Hz. 14000-23000 scans were acquired, with a
recycle time time of 2s.
Spectra were processed on a Silicon Graphics workstation using
FELIX 2.30 (Hare Research). Prior to Fourier transformation,
a convolution was applied to the free induction decays to remove
the residual solvent resonance. The data were typically apodized
with a skewed sine bell with a 60°C phase shift. The H20
resonance was used as a 'H chemical shift reference at 4.78
ppm. 15N spectra were indirectly referenced to 15NH3.Y
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